1-10 of 10
Glenn Michelson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine

Lokesh Patil, Christine J. Gu, Cristina Tognon, Nicola Long, Kara Johnson, Melissa A Fischer, Somedeb Ball, Michael R. Savona, Chris Leonardi, Joseph Wagner, Glenn Michelson, Markus D. Lacher
Journal: Blood
Blood (2024) 144 (Supplement 1): 5818.
https://doi.org/10.1182/blood-2024-206299
Published: 2024
Journal Articles

Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Brian A. Jonas, Karen Yee, Alice Mims, Paul B. Koller, Joseph Brandwein, Gail J. Roboz, Glenn Michelson, Linh Nguyen, Mark R Bray, Emily Roberts-Thomson, Roger Sidhu, Gautam Borthakur
Journal: Blood
Blood (2023) 142 (Supplement 1): 4294.
https://doi.org/10.1182/blood-2023-182027
Published: 2023
Journal Articles

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S Khodadoust, MDPhD, Youn H. Kim, MD, Javier Munoz, MD, Manish R Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Andrew Steele, Anjali Pandey, PhD, Matt R Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn Michelson, MD, Gregory P. Coffey, PhD, John T Curnutte, MD PhD, Paul A. Hamlin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1001.
https://doi.org/10.1182/blood-2018-99-119944
Published: 2018
Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2782.
https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782
Published: 2017
Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2016) 128 (22): 2768.
https://doi.org/10.1182/blood.V128.22.2768.2768
Published: 2016
Journal Articles

Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates

Greg P. Coffey, PhD, Jiajia Feng, MD, Glenn Michelson, MD, Janet Leads, PhD, John T. Curnutte, MDPhD, Anjali Pandey, PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2015) 126 (23): 3706.
https://doi.org/10.1182/blood.V126.23.3706.3706
Published: 2015
Journal Articles

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Paul A Hamlin, Jr., MD, Ian Flinn, MD, Nina wagner-Johnston, MD, Jan A Burger, MD PhD, Glenn Michelson, MD, Anjali Pandey, PhD, Matt Birrell, Greg P. Coffey, PhD, Janet M Leeds, PhD, John T. Curnutte, MDPhD, Manish R. Patel, MD
Journal: Blood
Blood (2015) 126 (23): 3929.
https://doi.org/10.1182/blood.V126.23.3929.3929
Published: 2015
Journal Articles

Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia.

Jeffrey Lancet, MD, Judith E. Karp, MD, Larry D. Cripe, MD, Gail J. Roboz, MD, Matt Suster, Nguyen Tan, Rachael Hawtin, Judith Fox, Craig Berman, Glenn Michelson
Journal: Blood
Blood (2008) 112 (11): 1955.
https://doi.org/10.1182/blood.V112.11.1955.1955
Published: 2008
Journal Articles

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Jeffrey Lancet, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Sem Bastien, R.N., Katrina Alino, R.N., Glenn Michelson, M.D., Judith Karp, M.D.
Journal: Blood
Blood (2007) 110 (11): 442.
https://doi.org/10.1182/blood.V110.11.442.442
Published: 2007
Journal Articles

Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion.

Sandra Milan, Deborah Hurst, Glenn Michelson, Emil Samara
Journal: Blood
Blood (2004) 104 (11): 4627.
https://doi.org/10.1182/blood.V104.11.4627.4627
Published: 2004